Poor
Not Aligned
Patient Risk:
Moderate
Summary
The AI statements are largely about different products (Namenda/Namenda XR) and different indications than the provided label content (memantine+donepezil extended-release capsules). Only very general statements about memantine (e.g., NMDA antagonist) are potentially consistent, but many product-specific claims (formulation, dosing frequency, side effects list, and developer/company history) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Memantine hydrochloride is an N-methyl-D-aspartate (NMDA) receptor antagonist.
Supported by the provided label excerpt in Clinical Pharmacology 12.1: “Memantine… [NMDA antagonist]”.
Memantine hydrochloride modulates the effects of glutamate.
Potentially consistent with the provided label describing memantine as an NMDA antagonist, but the provided excerpts explicitly state NMDA antagonist rather than “modulates glutamate” wording; support is not direct from the pasted excerpts.
Memantine hydrochloride blocks excessive NMDA receptor activation.
Not directly stated in the provided excerpts; only “NMDA antagonist” is explicitly provided.
Both Namenda XR and Namenda contain memantine hydrochloride as the active ingredient.
Not supported by the provided label excerpts, which are for “memantine and donepezil hydrochlorides extended-release capsules.”
Unsupported Statements
Memantine hydrochloride 10 mg is available as Namenda XR, a once-daily extended-release capsule.
Not supported by the provided label excerpts; provided excerpts are for memantine+donepezil extended-release capsules, not Namenda/Namenda XR product strengths and dosing.
Memantine hydrochloride 10 mg is available as Namenda, a twice-daily immediate-release tablet.
Not supported by the provided label excerpts; provided excerpts do not describe Namenda immediate-release products.
U.S. Patent No. 8,440,652, which relates to the extended-release formulation, expired on August 5, 2023.
Patent status/expiration date is not included in the provided label excerpts.
Memantine hydrochloride is used to treat moderate to severe dementia of the Alzheimer's type.
Provided label excerpts indicate the indicated product is “memantine and donepezil hydrochlorides extended-release capsules.” The AI claim omits donepezil and therefore is not supported by the provided label text.
Namenda XR is an extended-release formulation taken once daily.
Not supported by the provided label excerpts.
Namenda is an immediate-release formulation taken twice daily.
Not supported by the provided label excerpts.
Namenda XR and Namenda are used to treat moderate to severe Alzheimer's disease.
Not supported by the provided label excerpts; the excerpted indication is for memantine+donepezil extended-release capsules.
Common side effects of memantine hydrochloride can include dizziness.
The provided adverse reaction excerpt mentions “headache, diarrhea, and dizziness” but this is for “memantine hydrochloride extended-release” within the context of the provided label; however, the AI attributes these as general “memantine hydrochloride” common side effects without matching the product context. Support is partial and not clearly tied to the exact product system described in the provided label excerpts.
Common side effects of memantine hydrochloride can include headache.
Partially supported by the provided adverse reaction excerpt (headache, diarrhea, dizziness) for memantine hydrochloride extended-release, but not clearly supported as a broad general statement for all memantine formulations.
Common side effects of memantine hydrochloride can include confusion.
Not supported by the provided adverse reaction excerpts.
Common side effects of memantine hydrochloride can include constipation.
Not supported by the provided adverse reaction excerpts.
Common side effects of memantine hydrochloride can include drowsiness.
Not supported by the provided adverse reaction excerpts.
Common side effects of memantine hydrochloride can include hallucinations.
Not supported by the provided adverse reaction excerpts.
The original developer of Namenda and Namenda XR was Forest Laboratories.
Company/developer history is not included in the provided label excerpts.
Forest Laboratories is now part of AbbVie.
Not included in the provided label excerpts.
Numerous pharmaceutical companies manufacture generic versions of memantine hydrochloride.
Not included in the provided label excerpts.
Memantine hydrochloride modulates the effects of glutamate.
Not explicitly stated in the provided excerpts; only “NMDA antagonist” language is provided.
Memantine hydrochloride blocks excessive NMDA receptor activation.
Not explicitly stated in the provided excerpts.
Contradictions
Low
AI Statement
Memantine hydrochloride is used to treat moderate to severe dementia of the Alzheimer's type.
Label Reference
Provided label indication states: “Memantine and donepezil hydrochlorides extended-release capsules are indicated…” (includes donepezil).
Important Omissions
The AI response fails to reference the provided label’s key indicated product combination (memantine AND donepezil) when making indication and product claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Product/indication mismatch (Namenda/Namenda XR vs memantine+donepezil extended-release capsules) and unsupported or potentially incorrect side effect claims could mislead about appropriate labeled use and expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims refer to Namenda/Namenda XR (memantine alone) and generic/developer/patent history, while the provided label excerpts are for memantine+donepezil extended-release capsules. Many side effect and formulation/dosing frequency claims are unsupported by the provided excerpts.
Suggested Improvement
Limit claims to the exact labeled product and label excerpts provided (memantine and donepezil hydrochlorides extended-release capsules), avoid company/patent statements, and only list adverse reactions that are explicitly present in the provided label text.